![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Perrigo Company |
---|---|
Information provided by: | Perrigo Company |
ClinicalTrials.gov Identifier: | NCT00803192 |
Compare the rate and extent of absorption of famotidine 40 mg tablets, administered as 1 x 40 mg tablet under fed conditions.
Condition | Intervention |
---|---|
Bioavailability |
Drug: Famotidine Tablets, 40 mg |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Bio-equivalence Study |
Official Title: | Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions |
Enrollment: | 44 |
Study Start Date: | June 2004 |
Primary Completion Date: | June 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Test Drug: Active Comparator | Drug: Famotidine Tablets, 40 mg |
Reference Drug: Active Comparator | Drug: Famotidine Tablets, 40 mg |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Perrigo ( Diane Morgan ) |
Study ID Numbers: | 40104 |
Study First Received: | December 3, 2008 |
Last Updated: | December 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00803192 History of Changes |
Health Authority: | Canada: Health Canada |
bioavailability famotidine |
Neurotransmitter Agents Malnutrition Histamine Antagonists Famotidine |
Histamine phosphate Healthy Histamine H2 Antagonists Histamine |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Histamine Antagonists Famotidine Therapeutic Uses Physiological Effects of Drugs |
Anti-Ulcer Agents Gastrointestinal Agents Histamine Agents Histamine H2 Antagonists Pharmacologic Actions |